Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront

Novartis licenses mRNA autoimmune therapy from Abogen for up to $7.8 billion

Novartis agreed to pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, with the deal valued at up to $7.8 billion including milestones. The mRNA-based therapy targets autoimmune diseases.